cisplatin + tegafur + uracil + vindesine

This is a four-drug combination chemotherapy regimen consisting of cisplatin, tegafur, uracil, and vindesine. Each component has a distinct mechanism of action targeting cancer cells: - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to DNA damage and apoptosis in rapidly dividing tumor cells. - **Tegafur** is an oral prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis. - **Uracil** acts as a biochemical modulator by inhibiting the degradation of 5-FU (from tegafur), thereby increasing its efficacy. - **Vindesine** is a vinca alkaloid that inhibits microtubule assembly, arresting cell division at metaphase. This combination has been studied primarily in the context of non-small cell lung cancer (NSCLC) as adjuvant or postoperative chemotherapy. The regimen aims to maximize antitumor activity through multiple mechanisms—DNA crosslinking/damage, inhibition of nucleotide synthesis, and disruption of mitosis—while leveraging oral administration for some components to improve patient convenience[2][3][8].